Cargando…

Validation of four cutaneous squamous cell carcinoma staging systems using nationwide data

BACKGROUND: Cutaneous squamous cell carcinoma (cSCC) is the second most common cancer worldwide with relatively low metastatic potential (2–5%). Developments in therapeutic options have highlighted the need to better identify high‐risk patients who could benefit from closer surveillance, adjuvant th...

Descripción completa

Detalles Bibliográficos
Autores principales: Venables, Zoe Claire, Tokez, Selin, Hollestein, Loes M., Mooyaart, Antien L., van den Bos, Renate Ruth, Rous, Brian, Leigh, Irene M., Nijsten, Tamar, Wakkee, Marlies
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9315012/
https://www.ncbi.nlm.nih.gov/pubmed/34862598
http://dx.doi.org/10.1111/bjd.20909
_version_ 1784754457480790016
author Venables, Zoe Claire
Tokez, Selin
Hollestein, Loes M.
Mooyaart, Antien L.
van den Bos, Renate Ruth
Rous, Brian
Leigh, Irene M.
Nijsten, Tamar
Wakkee, Marlies
author_facet Venables, Zoe Claire
Tokez, Selin
Hollestein, Loes M.
Mooyaart, Antien L.
van den Bos, Renate Ruth
Rous, Brian
Leigh, Irene M.
Nijsten, Tamar
Wakkee, Marlies
author_sort Venables, Zoe Claire
collection PubMed
description BACKGROUND: Cutaneous squamous cell carcinoma (cSCC) is the second most common cancer worldwide with relatively low metastatic potential (2–5%). Developments in therapeutic options have highlighted the need to better identify high‐risk patients who could benefit from closer surveillance, adjuvant therapies and baseline/follow‐up imaging, while at the same time safely omitting low‐risk patients from further follow‐up. Controversy remains regarding the predictive performance of current cSCC staging systems and which methodology to adopt. OBJECTIVES: To validate the performance of four cSCC staging systems [American Joint Committee on Cancer 8th edition (AJCC8), Brigham and Women’s Hospital (BWH), Tübingen and Salamanca T3 refinement] in predicting metastasis using a nationwide cohort. METHODS: A nested case–control study using data from the National Disease Registration Service, England, 2013–2015 was conducted. Metastatic cSCC cases were identified using an algorithm to identify all potential cases for manual review. These were 1 : 1 matched on follow‐up time to nonmetastatic controls randomly selected from 2013. Staging systems were analysed for distinctiveness, homogeneity, monotonicity, specificity, positive predictive value (PPV), negative predictive value (NPV) and c‐index. RESULTS: We included 887 metastatic cSCC cases and 887 nonmetastatic cSCC controls. The BWH system showed the highest specificity [92.8%, 95% confidence interval (CI) 90.8–94.3%, PPV (13.2%, 95% CI 10.6–16.2) and c‐index (0.84, 95% CI 0.82–0.86). The AJCC8 showed superior NPV (99.2%, 95% CI 99.2–99.3), homogeneity and monotonicity compared with the BWH and Tübingen diameter and thickness classifications (P < 0.001). Salamanca refinement did not show any improvement in AJCC8 T3 cSCC staging. CONCLUSIONS: We validated four cSCC staging systems using the largest nationwide dataset of metastatic cSCC so far. Although the BWH system showed the highest overall discriminative ability, PPV was low for all staging systems, which shows the need for further improvement and refining of current cSCC staging systems.
format Online
Article
Text
id pubmed-9315012
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-93150122022-07-30 Validation of four cutaneous squamous cell carcinoma staging systems using nationwide data Venables, Zoe Claire Tokez, Selin Hollestein, Loes M. Mooyaart, Antien L. van den Bos, Renate Ruth Rous, Brian Leigh, Irene M. Nijsten, Tamar Wakkee, Marlies Br J Dermatol Original Articles BACKGROUND: Cutaneous squamous cell carcinoma (cSCC) is the second most common cancer worldwide with relatively low metastatic potential (2–5%). Developments in therapeutic options have highlighted the need to better identify high‐risk patients who could benefit from closer surveillance, adjuvant therapies and baseline/follow‐up imaging, while at the same time safely omitting low‐risk patients from further follow‐up. Controversy remains regarding the predictive performance of current cSCC staging systems and which methodology to adopt. OBJECTIVES: To validate the performance of four cSCC staging systems [American Joint Committee on Cancer 8th edition (AJCC8), Brigham and Women’s Hospital (BWH), Tübingen and Salamanca T3 refinement] in predicting metastasis using a nationwide cohort. METHODS: A nested case–control study using data from the National Disease Registration Service, England, 2013–2015 was conducted. Metastatic cSCC cases were identified using an algorithm to identify all potential cases for manual review. These were 1 : 1 matched on follow‐up time to nonmetastatic controls randomly selected from 2013. Staging systems were analysed for distinctiveness, homogeneity, monotonicity, specificity, positive predictive value (PPV), negative predictive value (NPV) and c‐index. RESULTS: We included 887 metastatic cSCC cases and 887 nonmetastatic cSCC controls. The BWH system showed the highest specificity [92.8%, 95% confidence interval (CI) 90.8–94.3%, PPV (13.2%, 95% CI 10.6–16.2) and c‐index (0.84, 95% CI 0.82–0.86). The AJCC8 showed superior NPV (99.2%, 95% CI 99.2–99.3), homogeneity and monotonicity compared with the BWH and Tübingen diameter and thickness classifications (P < 0.001). Salamanca refinement did not show any improvement in AJCC8 T3 cSCC staging. CONCLUSIONS: We validated four cSCC staging systems using the largest nationwide dataset of metastatic cSCC so far. Although the BWH system showed the highest overall discriminative ability, PPV was low for all staging systems, which shows the need for further improvement and refining of current cSCC staging systems. John Wiley and Sons Inc. 2022-03-26 2022-05 /pmc/articles/PMC9315012/ /pubmed/34862598 http://dx.doi.org/10.1111/bjd.20909 Text en © 2021 The Authors. British Journal of Dermatology published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Venables, Zoe Claire
Tokez, Selin
Hollestein, Loes M.
Mooyaart, Antien L.
van den Bos, Renate Ruth
Rous, Brian
Leigh, Irene M.
Nijsten, Tamar
Wakkee, Marlies
Validation of four cutaneous squamous cell carcinoma staging systems using nationwide data
title Validation of four cutaneous squamous cell carcinoma staging systems using nationwide data
title_full Validation of four cutaneous squamous cell carcinoma staging systems using nationwide data
title_fullStr Validation of four cutaneous squamous cell carcinoma staging systems using nationwide data
title_full_unstemmed Validation of four cutaneous squamous cell carcinoma staging systems using nationwide data
title_short Validation of four cutaneous squamous cell carcinoma staging systems using nationwide data
title_sort validation of four cutaneous squamous cell carcinoma staging systems using nationwide data
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9315012/
https://www.ncbi.nlm.nih.gov/pubmed/34862598
http://dx.doi.org/10.1111/bjd.20909
work_keys_str_mv AT venableszoeclaire validationoffourcutaneoussquamouscellcarcinomastagingsystemsusingnationwidedata
AT tokezselin validationoffourcutaneoussquamouscellcarcinomastagingsystemsusingnationwidedata
AT hollesteinloesm validationoffourcutaneoussquamouscellcarcinomastagingsystemsusingnationwidedata
AT mooyaartantienl validationoffourcutaneoussquamouscellcarcinomastagingsystemsusingnationwidedata
AT vandenbosrenateruth validationoffourcutaneoussquamouscellcarcinomastagingsystemsusingnationwidedata
AT rousbrian validationoffourcutaneoussquamouscellcarcinomastagingsystemsusingnationwidedata
AT leighirenem validationoffourcutaneoussquamouscellcarcinomastagingsystemsusingnationwidedata
AT nijstentamar validationoffourcutaneoussquamouscellcarcinomastagingsystemsusingnationwidedata
AT wakkeemarlies validationoffourcutaneoussquamouscellcarcinomastagingsystemsusingnationwidedata